Crinetics price target lowered to $105 from $108 at Citizens

Citizens analyst Jonathan Wolleben lowered the firm’s price target on Crinetics (CRNX) to $105 from $108 and keeps an Outperform rating on the shares. An initial survey of U.S. endocrinologists indicates a positive early launch experience for Palsonify, supporting the previously announced Q1 top-line beat and suggesting adoption and performance are tracking ahead of expectations, the analyst tells investors in a research note The launch is expected to continue outperforming through 2026, with sales projected above consensus and momentum supported by ongoing pipeline execution and upcoming clinical milestones, the firm says.